39 drugs will increase in price

01 A batch of drugs increased in price

Recently, the Gansu Provincial Public Resources Trading Center issued the "Notice on Announcement of the Market Approval Results of the 2020 Drug Centralized Procurement Dynamic Adjustments to Proposed Price Increases
.

According to the notice, there are 2031 drugs to be increased in the dynamic adjustment of centralized drug procurement in 2020, of which 39 meet the price adjustment conditions, 358 have applied for an extension of the market approval window, and 7 enterprises will be adjusted after the establishment of an enterprise complaint and will be adjusted after expert evaluation.
1,626 applications for abandoning price adjustments or not applying for price adjustments were deemed as abandoning price adjustments (see the end of the article for details)
.

The results of the adjustment will be implemented on August 10, 2021.
Drugs that meet the price adjustment conditions will be adjusted on the platform and prices from the date of implementation.
Medical institutions across the province will purchase at the new price, and the Sunshine platform bargaining price shall not be higher than the dynamic adjustment quotation of the enterprise
.

If the enterprise applies for abandoning the price adjustment or does not apply for the drugs deemed as abandoning the price adjustment, the price will be executed in accordance with the original bid-winning price
.

Drugs that apply for an extension of the market approval window will continue to retain their qualifications for market approval, and the platform and bid-winning prices will not be updated, and the purchase volume at the new declared price shall reach 90% of the total purchase volume of the previous year (not less than 5 companies).
Procurement by medical institutions above the national level), price adjustments can be made after expert argumentation
.

For drugs that were not purchased in the previous year, the purchase amount at the new declared price reaches 90% of the total purchase amount this year (not less than 5 second-level or higher medical institutions purchase), and price adjustments can be made after expert argumentation
.

02 Price adjustment window

Controlling drug prices is the core of medical reform.
In recent years, the direction of drug adjustments has also focused on price reductions.
There are also certain restrictions on drug price increases this time
.

According to the documents, the bid-winning drug company must meet the following conditions to apply for an increase in the winning bid price or the online reference price:

(1) It must be a drug in the dynamic adjustment catalog of the current year
.

(2) The application price shall not be higher than the national minimum bid-winning online price for the drug being implemented.
If the online price is the enterprise's self-quotation, it shall be declared at the lowest actual transaction price in the province
.

(3) The application price sets a three-month market approval window period, and the platform publicity and variety dynamic adjustments are carried out first
.

It can be seen that according to the price increase regulations of Gansu Province, there are more restrictions and the price increase is limited.
The state is more of a window for drug companies to adjust prices
.

The document shows that the implementation of this policy is to ensure the quality and supply of medicines
.

On November 7, 2018, the Liaoning Pharmaceutical Collection Center issued the 2018 Early Warning Forecast for Shortage Drugs No.
3, stating that 54 drugs could not be supplied and distributed normally.
After the investigation, 15 pharmaceutical companies still reported that they were affected by raw materials and the transformation of their production lines.
This resulted in insufficient production capacity; 6 pharmaceutical companies reported that they had stopped production because they could not purchase raw materials; 2 drugs could not be supplied normally due to rising prices of raw materials and low bid-winning prices
.

Regarding this matter, the general opinion in the industry is that the price increase of raw materials and the low bid price of the medicine are the reasons why the supply cannot be guaranteed
.

03 Strengthen monitoring

In order to ensure the supply of medicines, the state has successively introduced a number of policies
.

Documents such as the "Opinions of the General Office of the State Council on Further Doing a Good Job in Guaranteeing Supply and Stabilization of Drugs in Shortage" and the "Opinions of the National Medical Security Administration on Doing a Good Job in Current Drug Price Management" all mention strengthening the testing of drug prices and the process of drug use.
Management
.

Recently, the National Medical Insurance Administration issued the "Notice on Carrying out Monitoring of Abnormal Changes in Drug Prices and Supply
.

In the notice, the National Medical Insurance Administration also delineated a “list of drugs for key monitoring of abnormal price and supply fluctuations” involving 142 varieties, involving arubicin injection, cytarabine injection, atropine injection, aminophylline Tablets and other common drugs that are prone to clinical shortages
.

Medicine is a special commodity, and its price needs to be subject to certain restrictions.
However, in the market, it is affected by the rising cost of raw materials, the rising cost of materials such as auxiliary materials and packaging materials, and the improvement of technical quality standards, which will actually lead to an increase in production costs
.